BALVERSA™ (erdafitinib) received FDA approval for treatment of patients with mUC
Janssen announced that BALVERSA™ (erdafitinib) received accelerated approval from the FDA for treatment of adults with locally advanced or metastatic urothelial carcinoma which has susceptible fibroblast growth factor receptor 3 or FGFR2 genetic alteration. April 12, 2019